Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 144 The United Laboratories International Holdings Limited Annual Report 2025 37. FINANCIAL INSTRUMENTS (Continued) Financial risk management objectives and policies (Continued) Credit risk and impairment assessment (Continued) Changes in the loss allowance for bills and other receivables are mainly due to: 2025 2024 Increase Increase (decrease) in (decrease) in 12m ECL 12m ECL RMB’000 RMB’000 Newly originated other receivables balance with gross amount of RMB106,404,000 (2024: RMB106,454,000) 13,171 11,551 Settlement in full of other receivables with a gross carrying amount of RMB106,454,000 (2024: RMB97,250,000) (11,551) (5,944) Newly originated banker’s acceptance bills receivables balance with gross amount of RMB1,982,202,000 (2024: RMB3,333,266,000) 174 212 Settlement in full of banker’s acceptance bills receivables balance with gross amount of RMB3,333,266,000 (2024: RMB3,496,731,000) (212) (193)